IL305381A - T-type calcium channel antagonists and their uses - Google Patents

T-type calcium channel antagonists and their uses

Info

Publication number
IL305381A
IL305381A IL305381A IL30538123A IL305381A IL 305381 A IL305381 A IL 305381A IL 305381 A IL305381 A IL 305381A IL 30538123 A IL30538123 A IL 30538123A IL 305381 A IL305381 A IL 305381A
Authority
IL
Israel
Prior art keywords
mirol
alkyl
cycloalkyl
compound
level
Prior art date
Application number
IL305381A
Other languages
English (en)
Hebrew (he)
Original Assignee
Univ Leland Stanford Junior
Acurex Biosciences Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leland Stanford Junior, Acurex Biosciences Corp filed Critical Univ Leland Stanford Junior
Publication of IL305381A publication Critical patent/IL305381A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL305381A 2021-03-04 2022-03-03 T-type calcium channel antagonists and their uses IL305381A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163156806P 2021-03-04 2021-03-04
US202163228505P 2021-08-02 2021-08-02
PCT/US2022/018682 WO2022216386A2 (en) 2021-03-04 2022-03-03 T-type calcium channel antagonists and uses thereof

Publications (1)

Publication Number Publication Date
IL305381A true IL305381A (en) 2023-10-01

Family

ID=83545681

Family Applications (1)

Application Number Title Priority Date Filing Date
IL305381A IL305381A (en) 2021-03-04 2022-03-03 T-type calcium channel antagonists and their uses

Country Status (10)

Country Link
US (1) US20240190865A1 (cg-RX-API-DMAC7.html)
EP (1) EP4301759A4 (cg-RX-API-DMAC7.html)
JP (1) JP7884740B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230167035A (cg-RX-API-DMAC7.html)
AU (1) AU2022255225A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023016601A2 (cg-RX-API-DMAC7.html)
CA (1) CA3208202A1 (cg-RX-API-DMAC7.html)
IL (1) IL305381A (cg-RX-API-DMAC7.html)
MX (1) MX2023010175A (cg-RX-API-DMAC7.html)
WO (1) WO2022216386A2 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024081653A2 (en) * 2022-10-12 2024-04-18 Acurex Biosciences Corporation Methods of lowering miro2 to treat neurodegenerative diseases
US20260174741A1 (en) * 2022-10-31 2026-06-25 Acurex Biosciences Corporation Methods of reducing miro1 or phosphorylated alpha-synuclein
CN116813444A (zh) * 2023-06-28 2023-09-29 福建凯昕药业有限公司 一种1-溴-4-(1-(三氟甲基)环丙基)苯的制备方法
IT202400013555A1 (it) * 2024-06-13 2025-12-13 Iama Therapeutics S R L Derivati benzoimidazolici come inibitori di nkcc1

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610701B2 (en) * 2001-02-09 2003-08-26 Merck & Co., Inc. Thrombin inhibitors
US7875636B2 (en) * 2006-04-12 2011-01-25 Merck Sharp & Dohme Corp. Pyridyl amide T-type calcium channel antagonists
KR20100072266A (ko) * 2007-10-24 2010-06-30 머크 샤프 앤드 돔 코포레이션 헤테로사이클 페닐 아미드 t-형 칼슘 채널 길항제
CA2702126A1 (en) * 2007-10-24 2009-04-30 Merck Sharp & Dohme Corp. Heterocycle amide t-type calcium channel antagonists
US8987310B2 (en) * 2009-10-30 2015-03-24 Merck Sharp & Dohme Corp. Heterocycle amide T-type calcium channel antagonists
CN114929242A (zh) * 2019-09-05 2022-08-19 小利兰·斯坦福大学托管委员会 修饰线粒体功能的方法和化合物

Also Published As

Publication number Publication date
MX2023010175A (es) 2023-09-07
WO2022216386A9 (en) 2022-12-01
JP7884740B2 (ja) 2026-07-06
US20240190865A1 (en) 2024-06-13
JP2024508903A (ja) 2024-02-28
WO2022216386A3 (en) 2023-01-12
CA3208202A1 (en) 2022-10-13
WO2022216386A2 (en) 2022-10-13
EP4301759A4 (en) 2025-09-24
EP4301759A2 (en) 2024-01-10
KR20230167035A (ko) 2023-12-07
AU2022255225A1 (en) 2023-09-21
BR112023016601A2 (pt) 2023-12-12

Similar Documents

Publication Publication Date Title
US20240190865A1 (en) T-type calcium channel antagonists and uses thereof
JP2022001573A (ja) 診断及び療法のための二環式化合物
JP6359720B2 (ja) キナーゼ調節のための化合物および方法、ならびにそれに対する適応症
AU2010338712B2 (en) Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor
TWI504604B (zh) 雜環化合物及其用途
US9932335B2 (en) Pyrrolopyridine or pyrazolopyridine derivatives
KR20210022675A (ko) 피리디닐 및 피라지닐-(아자)인돌설폰아미드
AU2015252654B2 (en) Polyfluorinated compounds acting as Bruton's tyrosine kinase inhibitors
KR20140022063A (ko) 신경 변성 질환을 치료하기 위한 방법 및 조성물
JP2002105085A (ja) 新規イミダゾチアゾール誘導体
KR20040077861A (ko) 5-하이드록시트립타민-6 리간드로서의 아자인돌릴알킬아민유도체
KR20180110132A (ko) 무스카린성 아세틸콜린 수용체 m1의 양성 알로스테릭 조절제
KR20190112022A (ko) 단백질 응집의 조절제로서의 바이사이클릭 비스-헤테로아릴 유도체
JP2021520340A (ja) 化合物およびpde4活性剤としてのそれらの使用
CN114591352B (zh) 一种三唑并哒嗪类化合物及其应用
TW202421130A (zh) 作為pi3k抑制劑的異喹啉酮
SG194097A1 (en) Pyridopyrazine derivatives and their use
CN118284602A (zh) 作为钠通道活化剂的吡啶衍生物及其用途
JP2024506047A (ja) 化合物およびpde4活性剤としてのそれらの使用
WO2024081653A2 (en) Methods of lowering miro2 to treat neurodegenerative diseases
US20190152979A1 (en) Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group ii metabotropic glutamate receptors
EP4611744A1 (en) Methods of reducing miro1 or phosphorylated alpha-synuclein
US20250214989A1 (en) Naphthyridinone derivatives for the treatment of a disease or disorder
US20240201205A1 (en) Method for detecting neurological diseases using supramolecule polymer therapeutics
CN116917289A (zh) T型钙通道拮抗剂及其用途